Phaseline

Targets › PDCD1LG2

PDCD1LG2 (Programmed cell death 1 ligand 2): drug programs, companies and trials

17 programs from 17 companies in 37 trials: 20 Phase 1, 15 Phase 2, 2 Phase 3; Oncology; next expected readout Nov 2026.

Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production. (UniProt, Q9BQ51)

Open in Phaseline: the race on PDCD1LG2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiotheusPM8002
bispecific antibody targeting PD-L1 and VEGF
CD274, VEGFA, PDCD1LG2Phase 3SCLC; Triple Negative Breast Cancer(TNBC); NSCLC; Neuroendocrine Neoplasm …Jan 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineAdbelimumab
PD-1/PD-L1 pathway inhibitor; anti-PD-L1 monoclonal antibody
PDCD1LG2Phase 2Esophageal Squamous Cell CarcinomaDec 2026
National Cancer Institute (NCI)PDS01ADC
Anti-PD-L2 antibody-drug conjugate
PDCD1LG2Phase 2Cancer Of Prostate; Metastatic Colorectal Cancer (Mcrc); Prostate Cancer; Kaposi Sarcoma …Dec 2026
The First Affiliated Hospital of Zhengzhou UniversitySHR1701
PD-L1 and TGFβ dual inhibitor
PDCD1LG2, TGFB1Phase 2Advanced Gastric CancerJul 2027
Peking University Cancer Hospital & Institute[18F]F-PDL1-3
PD-L1-targeted radionuclide probe (18F-labeled imaging agent)
PDCD1LG2Phase 2Lung Cancer (NSCLC)Jul 2027
Hubei Cancer HospitalLvonescimab (AK112)
PD-L2 inhibitor
PDCD1LG2Phase 2Breast CancerSep 2027
Fudan UniversityTQB2450
PD-L1 inhibitor
PDCD1LG2Phase 2Endometrial CancerOct 2027
Chia Tai Tianqing Pharmaceutical GroupBenmelstobart injection
PD-L1 inhibitor
PDCD1LG2Phase 2Alveolar Soft Part SarcomaNov 2027
Obstetrics & Gynecology Hospital of Fudan UniversityTuvonralimab
PD-L2 inhibitor
PDCD1LG2Phase 2Cervical CancersMar 2028
Boehringer IngelheimEzabenlimab
PD-L2 inhibitor antibody
PDCD1LG2Phase 1Carcinoma, Squamous Cell of Head and Neck (HNSCC); Solid Tumors; Small Cell Lung Carcinoma (SCLC); Neoplasms …Nov 2026
FBD BiologicsHCB301
Engineered SIRPα fused to anti-PD-L1 and TGF-β fusion protein
SIRPA, PDCD1LG2, TGFB1Phase 1Advanced Solid TumorDec 2026
MediLink Therapeutics (Suzhou)Ivonescimab (AK112)
Bispecific antibody targeting PD-L1 and CTLA-4
PDCD1LG1, PDCD1LG2Phase 1Advanced Solid TumorsJan 2027
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins[18F]DK222
PD-L1-targeted radiotracer for PET-CT imaging
PDCD1LG2Phase 1Non-Small Cell Lung CancerJan 2028
Jun ZhouIUAb190708
cytotoxic anti-PD-L1 antibody
PDCD1LG2Phase 1Solid Tumor CancerJun 2028
University of California, IrvineCOH06
Genetically engineered NK cells expressing PD-L1 and expressing/secreting IL-15
PDCD1LG2, IL15Phase 1Advanced Lung Non-Small Cell CarcinomaNov 2028
PfizerPF-08046054/SGN-PDL1V
PD-L1-targeted antibody-drug conjugate
PDCD1LG2Phase 1Advanced/Metastatic Non-Small Cell Lung CancerMar 2029
GSKIvonescimab
PD-L2 inhibitor
PDCD1LG2Phase 1Neoplasms, LungJun 2029

Conditions

SCLC (3) Cancer Of Prostate (2) Solid Tumors (2) Triple Negative Breast Cancer(TNBC) (1) NSCLC (1) Neuroendocrine Neoplasm (1) CRC (Colorectal Cancer) (1) Malignant Neoplasm (1) TNBC (1) Breast Cancer (1) Metastatic Colorectal Cancer (Mcrc) (1) Prostate Cancer (1)

Modalities

small molecule (8), antibody (5), mixed (4)

Companies

Biotheus (1) Hubei Cancer Hospital (1) National Cancer Institute (NCI) (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) FBD Biologics (1) Obstetrics & Gynecology Hospital of Fudan University (1) Boehringer Ingelheim (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) University of California, Irvine (1) GSK (1) Fudan University (1) Jun Zhou (1) The First Affiliated Hospital of Zhengzhou University (1) Chia Tai Tianqing Pharmaceutical Group (1) MediLink Therapeutics (Suzhou) (1) Pfizer (1) Peking University Cancer Hospital & Institute (1)

Related targets

TGFB1 (2) CD274 (1) VEGFA (1) SIRPA (1) IL15 (1) PDCD1LG1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.